A 24-week, double-blind, parallel group, placebo and active controlled study to investigate the efficacy and safety of daily oral roflumilast taken with low dose inhaled corticosteroids in patients with chronic asthma.

Trial Profile

A 24-week, double-blind, parallel group, placebo and active controlled study to investigate the efficacy and safety of daily oral roflumilast taken with low dose inhaled corticosteroids in patients with chronic asthma.

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Dec 2016

At a glance

  • Drugs Corticosteroids; Roflumilast
  • Indications Asthma
  • Focus Registrational; Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 04 May 2012 Company (Takeda Global Research and Development Center) added as trial sponsor as reported by ClinicalTrials.gov.
    • 30 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top